Angiotensin II for the treatment of vasodilatory shock: Enough data to consider angiotensin II safe?

Critical Care

Volumn 22, Issue 1, 2018, Pages

  Buchtele, Nina ^a   Schwameis, Michael ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CATECHOLAMINE; HYPERTENSIVE FACTOR; VASOCONSTRICTOR AGENT;

BACTERIAL TRANSMISSION; BLOOD PRESSURE REGULATION; BLOODSTREAM INFECTION; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; CRITICALLY ILL PATIENT; DELIRIUM; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ENTEROBACTERIACEAE; HUMAN; HYPOTENSION; INFECTION; LETTER; MESENTERIC ISCHEMIA; MORTALITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SHOCK; SIDE EFFECT; VASODILATATION;

ANGIOTENSIN II; HUMANS; SHOCK; VASOCONSTRICTOR AGENTS;

EID: 85045404412     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-018-2006-0     Document Type: Letter

References (8)

1. Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care. 2017;21(1):324.
2. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-30.
3. Antonucci E, Agosta S, Sakr Y. Angiotensin II in vasodilatory shock: lights and shadows. Crit Care. 2017;21(1):277.
4. Lamontagne F, Meade MO, Hebert PC, Asfar P, Lauzier F, Seely AJE, Day AG, Mehta S, Muscedere J, Bagshaw SM, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med. 2016;42(4):542-50.
5. Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, Jensen JU, Myburgh J, Singer M, Bellomo R, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med. 2016;42(12):1958-69.
6. Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45(8):1285-94.
7. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.
8. Sviri S, Hashoul J, Stav I, et al. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157-60.